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A novel, accurate, precise and economical stability indicating Reverse Phase-High Performance Liquid 
Chromatography (RP-HPLC) method, was developed and validated for the quantitative determination 
of ubidecarenone (UDC) in bulk drug, UDC marketed formulation and UDC loaded cubosomes (CBMs) 
nanocarriers through Response surface methodology (RSM) design with three factors and three levels 
was performed to optimize the chromatographic variables followed by forced degradation studies of 
UDC were performed to detect degradation peak. RP-HPLC separation was achieved using mobile 
phase consisting of Acetonitrile:Tetrahydrofuran:Deionised water in the ratio 55:42:3 and a flow rate 
of 1.0 mL/min was optimized with a standard retention time (Rt) of 2.15 min, through experiment. The 
method was found linear in the concentration range of 5-100 µg/mL with a regression coefficient of 
0.999. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 3.04 µg/mL 
and 9.11 µg/mL, respectively. 
Keywords: High Performance Liquid Chromatography/validation/stability. Response surface 
methodology (RSM). Ubidecarnenone (UDC)/evaluation.
INTRODUCTION
Ubidecarenone (UDC), also known as Coenzyme 
Q10 or Ubiquinone, is a natural antioxidant found in 
various plant and animal sources. UDC is a high molecular 
weight (863.34 g/Mol) hydrophobic drug molecule under 
BCS class II (Tran et al., 2001) (Figure 1). Absorption of 
UDC is very complex and associated with active transport 
mechanisms. UDC is absorbed as chylomicrons in the 
small intestine and then transported into the lymph to 
peripheral blood, but due to low aqueous solubility UDC 
has slow and limited absorption properties (Miles, 2007). 
Total body contents of UDC in healthy volunteer have been 
estimated to be 0.5-1.5 gm (Greenberg, Frishman, 1990). 
When administrated through the oral route, the time (Tmax) 
of peak plasma concentration (Cmax) was found to be ~6-8 
h (Hosoe et al., 2007). The reported prolonged elimination 
half-life in healthy volunteers following a single dose of 
deuterated UDC is ~ 33 h (Miles, 2007). UDC acts as 
antioxidant, cardioprotective, nephroprotective, membrane 
stabilizer and helps in the generation of ATP through the 
electron transport chain (Flowers, Hartley, Rees, 2013). 
Reduced form of UDC (UQH2) accepts electrons from the 
oxidized form of UDC (UQ. -) but is unable to hold it tightly, 
eventually donate the electron to another acceptor and thus 
UDC acts as an antioxidant (Ernster, Dallne, 1995; Kapoor, 
Kapoor, 2013). National cancer institute (NCI) reported low 
UDC blood levels in people with myeloma, lymphoma and 
cancers of the breast, lung, prostate, pancreas, colon, kidney 
and head and neck. The researchers further suggested that 
UDC helps the immune system and thus it may be useful 
as a secondary treatment of cancer.
Quality by design (QbD) Experimental designs are 
suitable tools to control and optimize the various variables. 
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In modern times, 3-level factorial designs which include, 
central composite design and Box-Behnken design, are 
being used for the optimization of formulation conditions 
(Graves et al., 1998). Box-Behnken design is the efficient 
approach to analyse the various process variables 
when the interaction between them is very complicated 
(Box, Behnken, 1960). The utility of Response surface 
methodology (RSM) for the analytical development 
and validation has been reported for several drugs e.g. 
lenalidomide (Hasnain et al., 2013) and amoxicillin 
trihydrate (Beg et al., 2012), but, no literature is available 
so far, for the optimized analytical method of UDC using 
RSM. Various High Performance Liquid Chromatography 
(HPLC) methods have been developed for the detection 
of UDC in blood plasma, raw materials and dietary 
supplements (Graves et al., 1998; Hansen et al., 2004; 
Lunetta, Roman, 2008). Several other analytical methods 
such as HPTLC, HPLC, APCI LC-MS and spectroscopic 
techniques had been previously employed to analyze the 
stability of UDC (Abdel-Kader et al., 2016; Lang, Packer, 
1987; Vadhanavikit et al., 1984). Lang and Parker (1987) 
reported a reverse phase HPLC (RP-HPLC) method with 
a step extraction procedure, UV detection, and a run time 
of about 20 min, for the estimation of UDC in biological 
fluids, raw materials and dietary supplements (Lang, 
Parker, 1987). But so far to our present knowledge, there 
was no RP-HPLC stability-indicating method for assessing 
UDC in bulk drug and pharmaceutical forms using a UV-
visible detector and a direct injection and a run time of 
2.15 min. The objective of the present investigation was 
to develop and validate a novel, simple, rapid, precise, 
economical and accurate RP-HPLC stability-indicating 
method for quantification of UDC in bulk drug and 
pharmaceutical formulation as per ICH guidelines using 
Design Expert®10.0 software (Stats-Ease) (ICH, 2005).
EXPERIMENTAL
Material
Ubidecarenone (UDC) was obtained from Mitsubishi 
Gas Chemical Company Inc. (Japan). Marketed soft 
gelatine capsule of UDC (brand name; I.Q 10B) containing 
10 mg of UDC was purchased through a local pharmacy. 
Acetonitrile, tetrahydrofuran, methanol, isopropyl alcohol 
and deionised water employed were of HPLC grade 
(Merck, India). Purified water was obtained from Milli-Q 
water purification system (Millipore) for conducting all 
the experiments. All other chemicals and reagents were 
of analytical grade and were purchased by Merck, India.
HPLC equipment and chromatographic conditions
HPLC analysis was performed on a Shimadzu 
system comprising of quaternary LC- 10A VP pumps, a 
variable-wavelength programmable UV-visible detector, 
SPD-10AVP column oven and a SCL 10AVP system 
controller consisting of 25 cm × 4.6 mm i.d., 5 μm particle, 
516 C18 DB reversed phase column (Phenomenex). 
A variety of mobile phases were investigated in the 
development of HPLC method suitable for analysis 
of UDC in the bulk drug. The selection of the mobile 
phase was based on sensitivity and suitability for drug 
content estimation. The mobile phase that consisted of 
acetonitrile (ACN), tetrahydrofuran (THF) and deionised 
water (DW) in different ratio was used which was filtered 
through a 0.20 µm pore size nylon membrane, degassed 
ultrasonically and pumped in isocratic mode at a flow 
rate as optimized using RSM. The Stock solution of UDC 
was prepared in an accurate volume of methanol (MeOH) 
and working standard solutions were freshly prepared by 
diluting the primary stock solutions with mobile phase 
during the time of analysis. Samples were injected by 
means of Rheodyne injector and elution of analytes was 
monitored at a wavelength of 275 nm (Table I).
Preparation of calibration curve
A Standard stock solution of UDC (1000 µg/mL) 
was prepared by dissolving accurately weighed amount of 
UDC (10 mg) in an accurate volume of MeOH in a 10 mL 
FIGURE 1 - Chemical structure of Ubidecarnenone.
TABLE I - HPLC instrument and chromatographic conditions
Process parameter Chromatographic conditions
Instrument Shimdazu (LC-10 AT VP)
Column 5 µm RP 18 (C18), 
Phenomenex®100, (250×4.6 mm)
Mobile phase ACN: THF: DW
Run time 10 min
Detector UV- Vis spectrophotometer
Detection wavelength 275 nm
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volumetric flask. The volume was made up to 10 mL with 
the mobile phase. The prepared solution was stored at 4 oC 
away from light. From this stock solution a concentration 
range of 5-100 µg/mL was prepared by further dilution. 
These diluted samples were filtered through 0.20 µm nylon 
membrane filter before analysis.
Optimization of analytical variables
The optimization of analytical variables was 
carried out using RSM. The mobile phase comprising 
the mixture of ACN, THF and DW was selected from 
preliminary screening. In Design Expert®10.0 software, 
the independent variables- ACN, THF and flow rate were 
entered with their actual levels. Box-Behnken design of 
experiments was followed with 3 factors, 2 levels and 17 
runs in the experimental design of analytical method (Box, 
Behnken, 1960). 
Yi = bo+ b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + 
b23X2X3 + b11X12 + b22X22 + b33X32
where, Yi is the dependent variable; bo is the intercept; 
b1 to b3 are the regression coefficients; X1, X2, X3 are the 
independent variables that were selected on the basis of 
pilot experiments. X1 acetonitrile, X2 tetrahydrofuran and 
X3 is the flow rate, while the dependent variables were 
retention time (Rt) and peak area, as shown in Table II.
Method validation
The analytical method was validated with respect 
to the ICH guidelines Q2 (R1) for parameters such as 
linearity, accuracy, precision, and specificity, limit of 
detection (LOD), limit of quantification (LOQ), robustness 
and ruggedness and forced degradation studies (ICH, 
2005).
Linearity and calibration range
A standard calibration curve of UDC was prepared 
using ten different concentrations, ranging from 5-100 µg/mL 
after serial dilution of stock solution (1000 µg/mL). Each 
concentration in the series was made each day to determine 
the linearity of UDC (n=3). The linear calibration curve of 
peak area versus drug concentration was plotted using the 
least square regression method and evaluated for linearity 
and range.
Accuracy as recovery
The recovery of the method was determined 
by spiking a previously analyzed test solution with 
the additional drug standard solution. Accuracy was 
determined by adding 50, 100 and 150% extra UDC to 
standard UDC solution (50 µg/mL) to evaluate the mean, 
standard deviation and relative standard of the peak area 
to their corresponding drug concentration.
Precision
The precision of the assay was determined by 
repeatability (intra-day) and intermediate precision (inter-
day). Repeatability refers to the use of analytical procedure 
within a laboratory over a short period of time that was 
evaluated by comparing the assays on different days. 
Inter- and intra-day variation, analysis of UDC solutions 
at three different concentrations (20, 40 and 60 µg/mL) 
were determined in triplicates as per ICH guidelines (ICH, 
2005). 
Limit of Detection (LOD) and Limit of Quantification 
(LOQ)
Limit of detection and limit of quantification was 
calculated by the method based on standard deviation of 
the response for the blank injection in triplicate and the 
slope (S) of the calibration curve. The peak area of the 
blank was calculated. The LOD and LOQ were determined 
using following formulae: 
LOD =3.3σ/S               LOQ = 10σ/S
Here σ is the standard deviation of the blank 
response and S is the slope of the calibration curve.
Robustness and ruggedness
The  p roposed  method  was  pe r fo rmed  by 
introducing slight changes in the chromatographic 
conditions such as wavelength for detection (±2nm), 
flow rate (±0.25%) and mobile phase composition 
(±5%). The effect in Rt was evaluated individually 
(n=3). The ruggedness of the method was assessed by 
comparison of the intra and inter-day assay result of 
UDC that has been performed by two analysts in the same 
laboratory.
TABLE II - Assigned values of the chromatographic variables 
with their levels in the response surface methodology
Factors
Levels
Low (-1) High (+1)
Acetonitrile (X1) (%) 50 60
Tetrahydrofuran (X2) (%) 38 46
Flow rate (X3) (mL/min) 0.75 1.25
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Forced degradation studies of UDC
Forced degradation studies were carried out to 
provide some information about the drug stability and 
to validate the specificity of the drug quantification of 
the assay. The standard solution of UDC was exposed to 
accelerated degradation by alkaline, acidic, oxidative and 
direct exposure to sunlight conditions.
Acid and alkaline induced degradation studies
Two aliquots of UDC standard (10 mg each) were 
dissolved in methanol in a 10 mL volumetric flask and 
volume was made up to 10 mL with 0.1 M HCL and 0.1 M 
NaOH separately to give strength of 1000 μg/ mL. The 
solutions were refluxed over 8 hours on an incubator at 80 
°C excluding the possible degradation by light. The resultant 
solutions were neutralized with 0.1 M HCL and 0.1 M 
NaOH. Further the resulting mixtures were diluted with 
mobile phase, ACN:THF:DW (55:42:3) to give the final 
concentration of 50 μg/mL and was injected for analysis.
Neutral degradation studies
To perform the neutral degradation (pH-7), 10 mg 
of UDC was dissolved in methanol in a 10 mL volumetric 
flask to give 1000 μg/mL of concentration. The resultant 
solution was refluxed and performed in the same manner 
as in alkaline and acidic degradation studies. The resultant 
solution was refluxed, diluted with mobile phase to a 
concentration of 50 μg/mL and was injected for analysis.
Hydrogen peroxide induced degradation studies
To perform the oxidative degradation, 10 mg of 
UDC was dissolved in methanol in a 10 mL volumetric 
flask and volume was made up to 10 mL with 3% hydrogen 
peroxide to give 1000 μg/mL of concentration. The 
solutions were refluxed over 8 hours on an incubator at 
80 °C. The resultant solution was refluxed, diluted with 
mobile phase to a concentration of 50 μg/mL and was 
injected for analysis.
Thermal induced degradation studies
Ten milligram (10 mg) of UDC were kept in a 
stability chamber at 100 °C for 24 hrs. The dried sample 
was dissolved in methanol and the volume made up to 10 
mL with ACN:THF:DW (55:42:3). The resultant solution 
was refluxed over 8 hrs in an incubator at 80 °C and further 
diluted with mobile phase to a concentration of 50 μg/mL 
before injecting for analysis. 
Photo induced degradation studies
For the photolytic degradation study of UDC, the 
experiment was performed in the presence of UV light 
(254 nm) for 24 hours and further exposure to sunlight for 
one day. 10 mg of light exposed drug was dissolved in a 
volumetric flask using methanol. The volume was made 
up to 10 mL using ACN: THF: DW (55:42:3) as a mobile 
phase to give 50 μg/mL of concentration and the final 
solution was injected for analysis.
Analysis of UDC in cubosomes (UDC-CBMs) and 
marketed dosage form
UDC-loaded cubosome (UDC-CBMs) were 
prepared by the fragmentation of glyceryl monooleate 
(GMO) in PF 127 and water, using modified dilution-
sonication method (Spicer et al., 2001). The obtained 
UDC-GCBMs had particle size in the range of 120-160 
nm (Muheem et al., 2017). UDC-GCBMs equivalent to 
10 mg of UDC i.e. 2 mL of UDC-GCBMs was taken in 
a 10 mL volumetric flask and sonicated in an ultrasonic 
bath for 5 min. The solution was further diluted with the 
mobile phase. The resultant solution was filtered using 
0.2 µm nylon membrane filter and injected for analysis.
Twenty capsules (each containing 10 mg UDC) 
were taken, and the powder was collected and weighed. 
An accurately weighed portion of the powder equivalent 
to 10 mg of UDC was taken in 10 mL volumetric flask. 
The sample was sonicated in ultrasonic bath for 5 min and 
further diluted with mobile phase. The resultant solution 
was filtered using 0.2 µm nylon membrane filter and 
injected for analysis. 
Statistical analysis
The experiments were carried out in triplicate (n=3) 
using freshly prepared samples. The results were then 
expressed as mean, standard deviation (SD) and relative 
standard deviation (RSD) of the peak areas and their 
corresponding concentrations were then calculated
RESULTS
Selection of mobile phase
The mobile phase was critically selected based on 
sensitivity, ease of preparation, availability, compatibility 
for stability studies, the time period for the analysis, the 
cost of solvents and most importantly the solubility of 
UDC in the mobile phase. Various mobile phases using 
different ratios of solvents such as ACN-THF-DW, ACN-
IPA-DW, THF-IPA-DW and ACN-MeOH-DW were 
studied for the analysis of UDC. Mobile phase consisting 
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of ACN-IPA-DW, THF-IPA-DW and ACN-MeOH-DW 
did not give any defined sharp peaks and had high Rt (Data 
not given). A Rt of 2.15 minutes with sharp peaks and no 
tailing was obtained with ACN: THF: DW.
Experimental design optimization
To identify the robust and optimized mobile phase 
composition the positive and/or negative interactions 
among the independent variables were traded off. The 
software generated 17 trials, given as coded variables, with 
the respective data for Rt and peak area, depicted in Table 
III. The response surfaces and the relationship between the 
independent variables ACN (X1), THF (X2), and flow rate 
(X3) on dependent variables, i.e., Rt (Y1) and peak area 
(Y2) are shown in Figure 2 (A-F). The Rt (Y1) was found 
to be influenced by the concentration of THF and flow 
rate. A nonlinear relationship was observed (Figure 2A), 
where the Rt proportionally decreases at initial levels and 
then increases with the increasing concentration of THF 
in the mobile phase mixture. A similar relationship was 
observed with the flow rate (Figure 2B). The concentration 
of THF and flow rate was found to influence the response 
variable (Y2). A curvilinear plot (Figure 2D-F) was obtained 
indicating a proportionate increase in peak area with 
increasing concentration of THF and flow rate, whereas with 
the gradual increase in ACN in mobile phase, a decrease in 
peak area was observed. As compared to other models, the 
classical second degree model with a quadratic experimental 
domain was suggested best by the design with the highest 
least squares regression value for response Y1 (r2 = 0.9515) 
and Y2 (r2 = 0.9733). Linear polynomial equations were 
studied to better understand the effect of interaction among 
the independent variables. The linear polynomial equations 
generated from ANOVA are depicted below:
Retention time (Y1) = + 2.14 +0.47X1 – 0.49X2 – 
0.86X3 – 0.23X1X2 – 0.31X1X3 – 0.16X2X3 – 
0.10X12 + 0.79X22 + 1.34X32
Peak Area (Y2) = + 87561.80 - 6880X1 + 9701.38X2 + 
18958.88X3 – 1171.0X1X2 + 3113.50X1X3 + 
2499.75X2X3 + 4963.47X12 + 1705.22X22 + 
7720.23X32
From the polynomial equations, it has been observed 
that all three independent variables with a positive 
FIGURE 2 - 3D-Response surface plots of (A) retention time and (B) Peak area for UDC
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sign indicates a positive effect on both the observed 
responses and negative sign showed a negative effect on 
both the observed responses. However, for Rt (Y1), the 
independent variable ACN (X1) has a positively influence 
on the Rt while the variable X2 and X3 favors the smaller 
value. However, the peak area (Y2) was found to be 
decreased with the variable X1 while a greater influence 
of X2 and X3 was observed.
Method validation
System suitability 
The % CV of peak area and Rt for UDC was found 
to be within 2%, indicating the suitability of the system. 
The number of theoretical plates and USP tailing factor 
for the six replicate injections were found to be 9265.5 ± 
1.5% and 1.38 ± 0.3% respectively.
Linearity and calibration range 
The standard calibration plot demonstrated a good 
relationship between concentration of UDC and area of the 
chromatogram over a concentration range of 5–100 μg/mL. 
The linear regression equation was y = 12589x - 26462 
with the regression coefficient of 0.999. The LOD and LOQ 
of the developed method were found to be 3.04 and 9.11 
μg/mL, respectively, which showed that the method was 
sensitive enough to detect and quantify UDC. Table IV 
summarizes the statistical data (n=3) for regression analysis.
Accuracy and precision 
The percentage recovery was found to be in the 
range of 99.94-102.29 ± 1.36%. The % RSD for recovery 
value is less than 2, thus satisfying the acceptance criteria 
(Table V). The % RSD for intra-day precision and for 
inter-day precision was found to be in the range of 0.39-0.9 
and 0.6-1.73, respectively. The developed method showed 
good precision and reproducibility with % RSD less than 
2, as listed in Table VI.
TABLE III - Experimental observed response in Box-Behnken 
design used for UDC method development
Trial X1 X2 X3 Y1 Y2
1 55 38 0.75 5.42 15,25,354
2 50 42 1.25 2.29 19,86,893
3 60 38 1 3.96 15,85,297
4 55 46 1.25 2.78 20,34,394
5 55 42 1 2.15 16,79,545
6 60 46 1 2.45 17,42,918
7 55 38 1.25 4.12 17,37,383
8 50 46 1 2.14 20,02,541
9 55 42 1 2.15 16,43,424
10 60 42 1.25 2.78 17,57,359
11 50 42 0.75 3.36 17,09,838
12 50 38 1 2.75 16,98,284
13 55 42 1 2.14 16,55,362
14 55 46 0.75 4.86 16,82,379
15 60 42 0.75 5.07 15,18,751
16 55 42 1 2.15 16,44,395
17 55 42 1 2.15 16,45,384
X1, Acetonitrile (%); X2, tetrahydrofuran (%); X3, flow rate 
(mL/min); Y1, retention time (minute); Y2, Peak area.
TABLE IV - Summary of linear regression data for the calibration 
plot (n=6) obtained from design of expert based design matrix
Statistical parameters HPLC Values
Linearity range (µg/mL) 5-100
Regressed equation Y = 12589X-26462
Correlation coefficient (R²) 0.999
Slope ± SD 12589 ± 102.320
Intercept ± SD 26462 ± 25.015
Limit of detection (µg/mL) 3.04
Limit of quantification (µg/mL) 9.11
TABLE V - Accuracy study data of the developed UDC HPLC method (n=3)
Excess drug added to 
analyte (%)
Theoretical content 
(μg/mL)
Concentration found 
(μg/mL) ± SD 
% Recovery % RSD
0 50 49.89 ± 0.19 99.78 0.380
50 75 75.25 ± 0.24 100.33 0.318
100 100 100.13 ± 0.27 100.13 0.269
150 125 125.53 ± 0.89 100.42 0.708
Cubosome formulation 50 49.43 ± 0.43 98.86 0.869
Marketed formulation 50 49.29 ± 0.74 98.58 1.50
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Robustness 
With small deliberate changes in chromatographic 
conditions no significant effect on Rt and peak area was 
observed. The results are presented in Table VII along with 
system suitability parameters of normal methodology. The 
influence of each variable on Rt of UDC was insignificant 
with % RSD > 2% implying the robustness of the method.
Forced degradation studies
To study the forced degradation, the UDC sample 
was exposed to 0.1 M HCl, 0.1 M NaOH, neutral, 3% 
H2O2, dry heat and UV light. The degradation peaks 
obtained were well distinguished from the parent peak. 
There were no significant changes in the Rt of UDC, but 
changes in peak areas were observed due to degradation 
metabolites eluted at different time points. The sample 
subjected to acidic stress showed a parent peak at 2.15 
min but a slight decrease in the area due to degradation of 
the parent drug in acidic condition was observed. In acidic 
stress condition the Rt of the metabolite peak was found 
to be 2.128 minutes with a % recovery of 95.63% (Figure 
3-(1) A). UDC sample kept under alkaline stress condition 
showed an intense metabolite peak at 1.994 minutes, 
as the sample was highly unstable under alkaline stress 
condition, the recovery decreased to 44.05% (Figure 3-(1) 
B). UDC sample kept in the oven at 100°C for 24 hours, 
upon dilution with subsequent injection showed the peak 
of parent drug at Rt of 2.18 min with recovery of 98.47% 
as shown in Figure 3-(2) (E). UDC sample was found to 
be stable under neutral condition with % recovery 81.32 
± 0.63% (Figure 3-(1) C). The UDC sample was found 
to be unstable under oxidative stresses with % recovery 
of 51.08% (Figure 3-(2) D). Rt of the parent as well as 
degradation metabolites with recoveries are summarized 
in Table VIII and Figure 3 (A–F). UDC is degraded in 
presence of light. UDC sample kept under photolytic 
condition showed two peak at 4.718 and 8.581. which 
depicted the degradation profile of UDC in Figure 3-2 (F). 
Analysis of UDC in cubosomes (UDC-CBMs) and 
marketed dosage form
The Rt for UDC in bulk drug, CBMs formulation 
and marketed dosage form was found to be 2.158, 2.156, 
2.179, respectively, confirming the stability of UDC in the 
formulation (Figure 4A-C). Furthermore, a single parent 
peak obtained in the analysis of CBMs confirms the fact 
that no excipient interaction occurred in the formulation. 
DISCUSSION
The method was optimized by the design of 
TABLE VI - Intra-day and inter-day precision study data of developed UDC HPLC method (n=3)
Concentration 
(µg/ml)
Repeatability (intra-day) Intermediate precision (inter-day)
Mean recovery 
(μg/mL) ± SD % RSD
Mean recovery 
(μg/mL) ± SD % RSD
20 19.2 ± 0.10 0.520 19.6 ± 0.12 0.612
40 38.7 ± 0.35 0.904  39.5 ± 0.29 0.734
60 58.6 ± 0.23 0.392 59.3 ± 0.61 1.02
Reproducibility of the developed UDC method
20 18.9 ± 0.09 0.476 19.7 ± 0.23 1.16
40 39.7 ± 0.23 0.579 39.1 ± 0.44 1.12
60 57.6 ± 0.51 0.885 58.7 ± 1.02 1.73
TABLE VII - Robustness study data of developed UDC HPLC 
method at different conditions (n=3)
Chromatographic 
conditions
Retention 
time % RSD
Optimized 
value
Wavelength of 
detection (nm)
274 2.17 0.46 275
275 2.15 0.27
276 2.15 0.27
Flow rate (mL/min)
0.98 2.18 0.55 1.0
1.0 2.16 0.37
1.02 2.19 0.36
% Deionised water
2.0 2.15 0.74 3.0
3.0 2.15 0.51
4.0 2.20 0.45
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FIGURE 3-(1) - Forced degradation chromatograms of UDC (A) acidic stress; (B) alkaline stress; (C) Neutral stress.
FIGURE 3-(2) - Forced degradation chromatograms of UDC (D) oxidation stress; (E) thermal stress; and (F) photolytic stress.
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experimental methodology which also furnished 
thoughtfully-thorough understanding of the factor–
response relationship and underlying interactions among 
them. The search for optimum condition was carried out 
through numerical optimization by ‘trading off’ various 
factors to attain the desired goals, that is maximization 
of peak area and theoretical plates and minimization 
of Rt and peak tailing to obtain desirability function 
closer to 1. The optimized condition obtained was, the 
mobile phase composition containing ACN (55%), THF 
(42%) and DW (3%) and flow rate (1 mL/min). The 
graphical optimization also yielded the optimum solution 
demarcate within the analytical design space as shown 
in the chromatogram of UDC (Figure 4A). A Rt of 2.15 
min was observed with a reasonable peak area within 
the defined limits. The analysis of the system suitability 
test demonstrated that the developed chromatographic 
conditions can be exploited to provide accurate data. 
The method was found to be precise (both intra-day and 
inter-day precision) and the results were found to be 
consistent with the repeatability of the method for the 
analysis of UDC in developed formulation. The obtained 
results for % recovery of UDC reference substance from 
formulation were found to be within the acceptable range, 
FIGURE 4 - HPLC chromatograms of UDC (A); UDC API (B); UDC peak in cubosome (C); and UDC peak in marketed dosage form.
TABLE VIII - Forced degradation studies data of UDC at various stress conditions
Degradation 
condition
Rt of UDC after 
exposure (min ± SD)
%RSD Rt of degradation 
products (min ± SD)
%RSD % Recovery after 
24 hours
Acidic 2.152 0.465 2.128 0.575 95.63 ± 0.24
Alkaline 2.150 0.189 1.998 0.466 44.05 ± 0.57
Neutral 2.129 0.697 2.083 0.669 81.32 ± 0.63
Oxidative 2.754 0.342 1.994 0.549 53.08 ± 0.58
Thermal 2.188 0.509 - - 98.47 ± 0.19
Photolytic 8.581 0.165 4.778 0.116 35.14 ± 0.76
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thus providing evidence that the proposed method was 
accurate. The result of robustness study showed that no 
significant effect was observed on Rt and area, with small 
deliberate changes in chromatographic conditions. There 
was no significant change in the Rt of UDC, but decrease 
in area was observed due to degradation metabolites 
eluted at different time points. The degradation peaks 
obtained were distinguishable from the parent peak. 
The method was highly advantageous vis-a-vis in terms 
of time, economy for determination of UDC formed 
during stress conditions, as evident from low Rt. The 
developed method was found to be sensitive which was 
evaluated in terms of LOD and LOQ. Further, the Rt of 
UDC in all the dosage forms was similar with respect to 
the standard UDC without any significant difference in 
the standard solution. Other parameters, like theoretical 
plates and peak tailing were found to be within the 
acceptable limits. Thus the developed method is a 
corroborated high degree of utility and can be exploited 
for the routine estimation of UDC in pharmaceutical 
formulations.
CONCLUSION
The method was optimized by design of experiment 
optimization technique using different variables. The 
measured signal was found to be precise, accurate 
and linear over the concentration range tested with a 
correlation coefficient of 0.999. Moreover, the lower 
solvent consumption along with the short analytical 
retention time of 2.15 min supports a cost effective and 
environmentally friendly chromatographic procedure. The 
forced degradation studies provided well distinguishable 
peaks of parent and degradation metabolites. Thus, the 
above validated method proved to be a rapid, selective, 
speciﬁc and accurate method which can be exploited for 
the separation of impurities and quantitative determination 
of UDC in API and pharmaceutical formulations. The 
corroborated method supports a high degree of practical 
utility for estimation of UDC in pharmaceutical dosage 
forms.
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